– USA, CA – Spyre Therapeutics, Inc. (NASDAQ: SYRE), a development-stage biotechnology company, today announced the appointment of Mark McKenna to its Board of Directors.
“Mark’s extraordinary career positions him to provide Spyre with valuable guidance as we seek to build a next-generation IBD company and create novel medicines with meaningfully improved efficacy and convenience compared to today’s standard of care. We look forward to incorporating Mark’s insights as we seek to demonstrate the clinical features of our antibodies in healthy volunteers this year and prepare to launch studies, including both monotherapies and combination treatments, in IBD patients next year,” said CEO, Dr. Cameron Turtle.
Concurrently, Alison Lawton has resigned from the Board effective February 1, 2024.
About Mark C. McKenna
Mark McKenna is the former President, CEO and Chairman of the Board of Directors of Prometheus Biosciences, Inc., which was acquired by Merck & Co., Inc. in June 2023 for approximately $10.8 billion. Before joining Prometheus, he was a corporate officer of Bausch Health and served as President of the subsidiary Salix Pharmaceuticals, where he revitalized Bausch’s gastroenterology business with a series of strategic acquisitions and product launches, doubling revenue to exceed $2 billion while enhancing operating margins. Before Salix, Mark McKenna spent more than a decade in various roles with Bausch + Lomb, also a division of Bausch, most recently as SVP and GM of its U.S. Vision Care business.
“Spyre had an impressive 2023, raising $390M through the capital markets with a syndicate of top-tier biotechnology investors,” said Mark McKenna. “They are now well positioned to advance their pipeline candidates into the clinic, and I am thrilled to contribute my passion and expertise to propel Spyre’s vision towards groundbreaking advancements in the treatment of IBD.”
Mark McKenna was Ernst & Young Entrepreneur of the Year in 2023 and holds a B.S. in marketing from Arizona State University and an MBA from Azusa Pacific University.
About Spyre Therapeutics
Spyre Therapeutics is a biotechnology company that aims to create next-generation inflammatory bowel disease (IBD) products by combining best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches. Spyre’s pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23.
SOURCE: https://spyre.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
